BNZ-111

BNZ-111 is a benzimidazole derivative and small molecule tubulin inhibitor developed as an oral anti-cancer drug. It demonstrates strong cytotoxic activity against both chemo-sensitive and chemo-resistant ovarian cancer cells, including those resistant to paclitaxel, by inducing apoptosis and causing G2/M cell cycle arrest. Preclinical studies indicate BNZ-111 is not a substrate for P-glycoprotein (P-gp) and exerts its effects by binding specifically to the β subunit of curved tubulin, thereby modulating β-3 tubulin expression and disrupting microtubule dynamics. BNZ-111 has shown significant in vivo tumor growth inhibition in platinum- and paclitaxel-resistant ovarian cancer models, with good oral exposure, bioavailability, and minimal general toxicity.

Other names

benzimidazole-2-amide BNZ-111benzimidazole2-amide BNZ-111benzimidazole 2-amide BNZ-111benzimidazole-2 propionamide BNZ-111benzimidazole2 propionamide BNZ-111benzimidazole 2 propionamide BNZ-111